Skip to main content
. 2022 Feb 17;3(3):194–207. doi: 10.1158/2643-3230.BCD-21-0160

Figure 4.

Figure 4. Prevalence and clinical outcome of UBTF-TDs in de novo AML cohorts. A, Frequencies of UBTF-TDs in published de novo AML cohorts in Supplementary Table S25. Statistical significance was calculated between the total pediatric and adult cohorts by Fisher exact test. B, Cytogenetic and genetic background of UBTF-TD cases in the AAML1031 cohort. C, Clinical outcomes of UBTF-TD cases and AML with major molecular features in the AAML1031 cohort. D, Minimal residual disease (MRD) positivity of UBTF-TD case with cooperating mutations of FLT3-ITD or WT1. E, Clinical outcomes of UBTF-TD cases with cooperating mutations of FLT3-ITD or WT1. F, Subgroup analysis of outcomes of UBTF-TDs with or without WT1 mutations within FLT3+ AMLs. In C, E, and F, the statistical significance of variables was tested with the log-rank test. In D, the statistical significance was calculated by Pearson χ2 test.

Prevalence and clinical outcome of UBTF-TDs in de novo AML cohorts. A, Frequencies of UBTF-TDs in published de novo AML cohorts in Supplementary Table S25. Statistical significance was calculated between the total pediatric and adult cohorts by Fisher exact test. B, Cytogenetic and genetic background of UBTF-TD cases in the AAML1031 cohort. C, Clinical outcomes of UBTF-TD cases and AML with major molecular features in the AAML1031 cohort. D, Minimal residual disease (MRD) positivity of UBTF-TD case with cooperating mutations of FLT3-ITD or WT1. E, Clinical outcomes of UBTF-TD cases with cooperating mutations of FLT3-ITD or WT1. F, Subgroup analysis of outcomes of UBTF-TDs with or without WT1 mutations within FLT3+ AMLs. In C, E, and F, the statistical significance of variables was tested with the log-rank test. In D, the statistical significance was calculated by Pearson χ2 test.